## KARUS

# Characterising the role of HDAC6 in the control of human macrophage IL-10 production

#### 92P, abstract 264

Philip Beer, Elisabeth Bone and Hilary McElwaine-Johnn Karus Therapeutics Ltd, Oxfordshire, United Kingdom

#### Background

Histone deacetylate 6 (HDAC6) is a protein deacetylase implicated in diverse cellular processes including cell signalling and motility.

✤ Interleukin 10 (IL-10) is a pleiotropic cytokine with both immunosuppressive and proinflammatory activity.

Clinical trials of therapeutic IL-10 administration have been undertaken in cancer and inflammatory disorders including rheumatoid arthritis and Crohn's disease.

Potentially counter to this, inhibition of IL-10 has also been linked with anti-tumour and anti-inflammatory properties.

✤ KA2309 & KA2508 are potent and selective inhibitors of HDAC6 identified as part of a clinical drug development programme; a closely related compound (KA2507) has completed a Phase I clinical trial in cancer without adverse tolerability signals (NCT03008018).

#### Methodology

MO macrophages were derived from the peripheral blood mononuclear cells of healthy human donors.

✤ M0 macrophages were differentiated *in vitro* into M2 macrophages in the presence or absence of test compounds at increasing concentrations.

Inhibitors of PI3-kinase and p38 MAP kinase were run as positive controls.

✤ At the end of the differentiation process, culture supernatants were collected for IL-10 quantification.

In vitro macrophage studies were performed by Explicyte, Bordeaux, France

#### Results


1. KA2309 & KA2508 are potent inhibitors of HDAC6 that are free from significant effects on other HDAC family enzymes.

	HDAC family biochemical IC <sub>50</sub> (nM)										
	1	2	3	4	5	6	7	8	9	10	11
KA2309	>10,000	>10,000	>10,000	>10,000	3,369	3	3,007	927	6,138	>10,000	>10,000
KA2508	7,935	>10,000	>10,000	2,615	701	4.1	695	162	2,356	>10,000	>10,000
					_		tod at				

	Ac-tubulin EC <sub>50</sub> (nM)	Ac-histone EC <sub>50</sub> (nM)	Acetylated α-tubulin, of on-target HDAC6 acetylated histone H3,
KA2309	153	15,753	of off-target class
KA2508	104	Not tested	inhibition, were quan human lung cancer cell

cetylated α-tubulin, a cellular marker f on-target HDAC6 inhibition, and cetylated histone H3, a cellular marker f off-target class I HDAC family nhibition, were quantitated in A549 uman lung cancer cells.

2. KA2309 demonstrates dose-dependent inhibition of IL-10 release from human *in vitro* cultured macrophages. The  $IC_{50}$  of this effect is similar to the  $EC_{50}$  for the induction of acetylated  $\alpha$ -tubulin in human and mouse tumour cell lines. *Comparable data were obtained for KA2508*.



#### Conclusions

### Selective inhibition of HDAC6 blocks the release of IL-10 from human macrophages.

Small molecule HDAC6 inhibition is feasible and well tolerated in man (based on a recent Phase I clinical trial of a sister compound).

Inhibition of IL-10 may enhance the anti-tumour immune response, although further work is required to understand the mechanisms.

✤ It has recently been suggested that IL-10 may play a role in the pathogenesis of severe COVID-19; inhibition of IL-10 may be beneficial in this setting<sup>1</sup>.

✤ Small molecule inhibitors of IL-10 release open the door for novel therapeutic avenues to be explored.

1. Lu et al, Trends Immunol. Epub 2 Nov 2020; PMID: 33214057

#### **Contact information**

For further information, please contact: Philip Beer Head of Research and Translational Medicine Karus Therapeutics Genesis Building, Library Avenue Harwell Campus, Oxfordshire, OX11 0SG United Kingdom p.beer@karustherapeutics.com